Stockreport

Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Shattuck Labs, Inc.  (STTK) 
PDF  – Announced development of SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A; IND filing expected in Q3'2025 –  – Cash balance of approxim [Read more]